Caris Life Sciences, a next-generation AI TechBio company and precision medicine specialist, announced on Friday the appointment of Dave Fredrickson to its board of directors, effective 15 August 2024.

Fredrickson is executive vice-president of the Oncology Business Unit at AstraZeneca plc and previously served as president of AstraZeneca KK Japan and vice president, Specialty Care of AstraZeneca US.

Fredrickson has served as vice chairman of the European Federation of Pharmaceutical Industries and Associations in Japan and director of the Japan Pharmaceutical Manufacturers Association, and held leadership positions at Roche/Genentech, including Oncology Business Unit Manager in Spain and strategy, marketing and sales roles in the United States. Additionally, he worked at strategy consultancy the Monitor Group LLC (now Monitor Deloitte Group LLC).

David Dean Halbert, DSc (h.c.), chairman, founder and CEO of Caris, said: "Dave's extensive leadership experience in global biopharma and knowledge of precision medicine development will provide a unique perspective to help us deliver on our vision to improve patient outcomes across multiple diseases worldwide."